AP NEWS

Advanced Bifurcation Systems Unveils at TCT 2018 Patented Stenting Platform Reducing Need for Open-Heart Surgeries

September 24, 2018

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Sep 24, 2018--Advanced Bifurcation Systems (ABS), a clinical-stage medical device company with a patented bifurcation stenting platform to standardize the treatment of all bifurcation lesions in coronary angioplasties, is showcasing its innovative platform at the ABS booth at Transcatheter Cardiovascular Therapeutics (TCT). The platform features the only modular self-aligning stent technology to evenly scaffold bifurcations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005301/en/

“Current statistics for bifurcation stenting show the highest stenting failure rates resulting in repeat revascularization procedures,” said Mehran Khorsandi, MD, interventional cardiologist and member of the HARTS stent team, Cedars-Sinai Medical Center, co-founder and CMO of ABS. “In the absence of an effective reproducible technology for addressing left main bifurcation disease, most patients are referred for open-heart surgery. The ABS technology overcomes the limitations of current approaches while simplifying the procedure.”

The ABS platform is a unique single system addressing main and side branches offering a disruptive bifurcation stenting technique that:

uses bifurcating stents deployed on a Mother/Daughter® (MD) monorail to branch and self-align covering bifurcations with no gaps; uses a dual-catheter system to move stents into position in one continuous process; eliminates gaps or overlaps and tangling of wires associated with current stent installations.

“Our stenting platform reduces the need for repeat procedures and enables effective bifurcation stenting treatment,” said ABS Chief Executive Officer Charles Laverty. “This simple procedure addresses a significant portion of patients who otherwise would be referred to open-heart surgery.”

ABS has filed a pre-submission with the FDA to define its clinical pathway leading to a PMA. The company also is defining its regulatory and clinical strategy for Europe to obtain a CE Mark.

About Advanced Bifurcation Systems

Advanced Bifurcation Systems, www.advancedbifurcation.com is a clinical-stage medical device company developing an innovative stenting platform for simple treatment of bifurcation lesions in coronary angioplasties.

About TCT

The Cardiovascular Research Foundation’s scientific symposium, Transcatheter Cardiovascular Therapeutics 2018 www.crf.org/tct is the world’s premier educational meeting specializing in interventional cardiovascular medicine taking place September 21-25 in San Diego.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005301/en/

CONTACT: For Advanced Bifurcation Systems:

Angie Ripullo, (949) 842-3120

aripullo@essentialhm.net

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: SURGERY HEALTH CARDIOLOGY CLINICAL TRIALS MEDICAL DEVICES RESEARCH FDA SCIENCE

SOURCE: Advanced Bifurcation Systems

Copyright Business Wire 2018.

PUB: 09/24/2018 10:00 AM/DISC: 09/24/2018 10:01 AM

http://www.businesswire.com/news/home/20180924005301/en

AP RADIO
Update hourly